Atlas Trials

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Clinical trial NCT02030847 · COMPLETED

Trial details

NCT number
NCT02030847
Sponsor
University of Pennsylvania
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Start date
2014-02-27
Primary completion
2018-04-26
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.